Fresenius Medical Care North America Introduces Frenova Renal Research

  Fresenius Medical Care North America Introduces Frenova Renal Research   Renal Research Organization is First of its Kind for Clinical Trial Services  Business Wire  WALTHAM, Mass. -- March 26, 2014  Fresenius Medical Care North America (FMCNA), the world’s largest provider of dialysis services, today introduced its newly branded Frenova Renal Research business, the only Phase I-IV drug and device clinical development partner dedicated exclusively to renal research.  Since 2001, Frenova, formerly known as the Clinical Studies Group at FMCNA, has supported sponsors and nephrologists conducting research specific to kidney disease and its comorbid conditions.  “Frenova is a new name, but the company is built on more than a decade of experience focused exclusively on the clinical development of new renal therapies largely developed using the world’s largest dialysis treatment and research network,” said Kurt Mussina, vice president and general manager of Frenova. Frenova provides access to a network comprising more than 390,000 pre-dialysis patients with chronic kidney disease (CKD) and 183,000 active dialysis patients with end stage renal disease (ESRD), as well as extensive resources of real-world clinical data collected over the past two decades.  These resources, combined with Frenova’s bioinformatics and analytics capabilities, provide an unparalleled asset for biopharmaceutical and medical device companies seeking to assess protocol feasibility, optimize research site selection and/or conduct highly targeted patient recruitment activities.  “The sheer depth of our renal expertise and our access to patients, sites, investigators and data resources for both cross-sectional and longitudinal analyses are indispensable assets for renal clinical development programs,” said Mussina. “Developing treatments to improve the quality of life for people with kidney disease has always been our singular objective. Our new identity as Frenova reflects that mission and will play a key role in furthering it,” Mussina added.  For more information, visit FrenovaRenalResearch.com or call 844.CKD.ESRD. Frenova will also be exhibiting at the 23rd Annual Partnerships in Clinical Trials — visit booth #402 or email Brigid.Flanagan@FrenovaRenalResearch.com to schedule a meeting.  About Frenova Renal Research  Frenova Renal Research, a Fresenius Medical Care North America (FMCNA) company, is the only Phase I-IV drug and device clinical development services provider dedicated exclusively to renal research. Backed by the world’s largest provider of dialysis services and a network of more than 390,000 active chronic kidney disease (CKD) patients and 183,000 active end stage renal disease (ESRD) patients, Frenova is an unparalleled resource for biotech, pharmaceutical and medical device companies worldwide. With comprehensive clinical development and bioinformatics and analytics services and an extensive renal site network, Frenova is your foremost renal research partner. Visit www.FrenovaRenalResearch.com for more information.  About Fresenius Medical Care North America  Through our leading network of more than 2,150 dialysis facilities in North America and our vascular access centers, laboratory, pharmacy and affiliated hospitals and nephrology practices, Fresenius Medical Care provides renal services to hundreds of thousands of people throughout the United States, Mexico and Canada. We are also the continent’s top producer of dialysis equipment, dialyzers and related disposable products and a major supplier of renal pharmaceuticals. For more information about the company, visitwww.fmcna.com; for information about patient services, visit www.ultracare-dialysis.com.  Contact:  Fresenius Medical Care North America Lea Studer, 308-237-5567 lea@scorrmarketing.com